Studies conducted at A. Friedli et al on angiogenesis recently published
2009 JUL 8 - (NewsRx.com) -- According to recent research from Villigen, Switzerland, "A soluble form of the L1 cell adhesion molecule (sL1) is released from various tumor cells and can be found in serum and ascites fluid of uterine and ovarian carcinoma patients. sL1 is a ligand for several Arg-Gly-Asp (RGD)-binding integrins and can be deposited in the extracellular matrix. In this study we describe a novel function of this physiologically relevant form of L1 as a pro-angiogenic factor." "We demonstrated that the anti-L1 monoclonal antibody (mAb) chCE7 binds near or to the sixth Ig-like domain of human L1 which contains a single RGD sequence. mAb chCE7 inhibited the RGD-dependent adhesion of ovarian carcinoma cells to sL1 and reversed the sL1-induced proliferation, matrigel invasion and tube formation of bovine aortic endothelial (BAE) cells. A combination of sL1 with vascular endothelial growth factor-A (VEGF-A(165)), which is an important angiogenic inducer in tumors, strongly potentiated VEGF receptor-2 tyrosine phosphorylation in BAE cells. Chick chorioallantoic membrane (CAM) assays revealed the proangiogenic potency of sL1 in vivo which could be abolished by chCE7," wrote A. Friedli and colleagues. The researchers concluded: "These results indicate an important role of released L1 in tumor angiogenesis and represent a novel function of antibody chCE7 in tumor therapy." Friedli and colleagues published their study in International Journal of Biochemistry & Cell Biology (The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. International Journal of Biochemistry & Cell Biology, 2009;41(7):1572-1580). For additional information, contact J. Grunberg, Paul Scherrer Institute, Center Radiopharmaceutical Science, ETH, USZ, CH-5232 Villigen, Switzerland. Publisher contact information for the International Journal of Biochemistry & Cell Biology is: Pergamon-Elsevier Science Ltd., the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England. Keywords: Switzerland, Villigen, Angiogenesis, Ascites, Biochemistry, Biotechnology, Cell Biology, Gynecology, Medical Device, Monoclonal Antibody, Oncology, Ovarian Cancer, Ovarian Carcinoma, Physiology, Tissue Engineering, Tumor Vascularization, Women's Health. This article was prepared by Immunotherapy Weekly editors from staff and other reports. Copyright 2009, Immunotherapy Weekly via NewsRx.com.
|
